Status: Recruiting
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study. Part A: randomised, double-blind, placebo-controlled, single ascending dose study. Part B: open label, multiple ascending dose study.
Participants needed: 52
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: BAR Pharmaceuticals s.r.l.Updated: Sep 22, 2025Locations: 1
Eligibility criteria
Informed consent: signed written informed consent before inclusion in the study [+11]
ECG 12-leads (supine position): clinically significant abnormalities, in particu... [+15]